Subscribe Become an Author Sign Up Log In

13th Annual Proteins & Antibodies Congress

   by BiopharmaTrend    188    Comments 0

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Oxford Global’s 13th Annual Proteins & Antibodies Congress will be attended by over 450 visionary leaders to network about the latest developments & participate in presentations from the areas of engineering, bioanalysis, biotherapeutics and bispecifics.

New for 2020 is the introduction of the kick-off sessions, providing an interactive experience for delegates through roundtable & panel discussions.  

Key Speakers Include:  

  • Tristan Vaughan, Vice President, AstraZeneca 
  • John McCafferty, Chief Executive Officer, IONTAS Pharmaceuticals 
  • Surinder Kaur, Director, Genentech 
  • Kristin Brown, Director, GlaxoSmithKline 

 

VIEW AGENDA: https://bit.ly/35Z0Rqw

Part of the Biologics Series, it is co-located with the 2nd Annual Bispecifics In Discovery & Development Congress and 7th Annual Peptides & Oligonucleotides Congress

2020 Live Webinar:

“Discovery & Clinical Collaborations In Biotherapeutics”

Hosted by Robin Löving, Chief Scientific Officer, Salipro Biotech & Denise Steckel, Head, Clinical Collaborations Management, Genentech

Wednesday 29th January 2020 | 4PM GMT

REGISTER FOR FREE: https://bit.ly/2PNKDKY

Go Social: Join our Proteins Network on LinkedIn, follow us on Twitter at @biologicsconf and join the conversation using the hashtag #Biologics20

For more information about the event, please contact Bradley Copeman at b.copeman@oxfordglobal.co.uk or visit the website: https://bit.ly/2Ts0qT5

 

Date: 27 - 29 April 2020

Location: London, UK

Share this:              

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *